# The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation

> **NCT07441967** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 44 (estimated)

## Conditions studied

- Hematologic Malignancies

## Interventions

- **DRUG:** Thiotepa
- **DRUG:** Fludarabine
- **DRUG:** G-CSF
- **DRUG:** cytarabine
- **DRUG:** busulfan

## Key facts

- **NCT ID:** NCT07441967
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-20
- **Primary completion:** 2027-12-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07441967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07441967, "The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07441967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*